aci-24
Vaccineexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02738450)
Timeline
Indications
Mechanism of action
- Beta amyloid A4 proteinImmunity, active
APP immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aci-24
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05462106 | Phase 1/Phase 2 (Phase 2) | Jun 21, 2022 | AC Immune SA, University of California, San Diego, Worldwide Clinical Trials |
| NCT04373616 | Phase 2 | Oct 31, 2020 | AC Immune SA, University of Southern California |
| NCT02738450 | Phase 1 | Mar 1, 2016 | AC Immune SA, LuMind Research Down Syndrome Foundation, National Institute on Aging (NIA), University of California, San Diego |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AC Immune SA | For profit | 3 | 3 | 2 | 2016 |
| University of California, San Diego | Academic/Hospital | 2 | 0 | 2 | 2016 |
| LuMind Research Down Syndrome Foundation | Academic/Hospital | 1 | 0 | 1 | 2016 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2016 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | 2022 |
6 organizations
Page 1 / 1